RT Journal Article
SR Electronic
T1 Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1713
OP 1717
DO 10.3899/jrheum.160275
VO 43
IS 9
A1 Arthur Kavanaugh
A1 Iain B. McInnes
A1 Philip J. Mease
A1 Stephen Hall
A1 Hector Chinoy
A1 Alan J. Kivitz
A1 Zailong Wang
A1 Shephard Mpofu
YR 2016
UL http://www.jrheum.org/content/43/9/1713.abstract
AB Objective. To determine the effect of prior tumor necrosis factor inhibitor (TNFi) therapy on secukinumab efficacy in psoriatic arthritis (PsA).Methods. Patients were randomized to secukinumab 300 mg, 150 mg, 75 mg, or placebo.Results. American College of Rheumatology 20 responses at Week 24 with secukinumab 300 mg, 150 mg, 75 mg, and placebo were 58.2%, 63.5%, 36.9%, and 15.9% in TNFi-naive (n = 258), and 45.5%, 29.7%, 14.7%, and 14.3% in TNFi-exposed patients (n = 139), respectively. Week 52 responses with secukinumab 300 mg, 150 mg, and 75 mg were 68.7%, 79.4%, and 58.5% in TNFi-naive, and 54.5%, 37.8%, and 35.3% in TNFi-exposed patients, respectively.Conclusion. Secukinumab was efficacious in TNFi-naive and TNFi-exposed patients with PsA, with greatest improvements in TNFi-naive patients.